Conditional internalization of PEGylated nanoparticles by using Anti-PEG bispecific antibodies
Updated time: 2021-10-21 17:36:58
Conditional internalization of PEGylated nanoparticles by using Anti-PEG bispecific antibodies
Docket Number
12A-1060522
IP Status
TW I742283
Abstract
The bispecific antibody can target PEGylated medicines or nanoparticles to specific cells or organs.
Technological Advantages
The bispecific antibodies can convert PEGylated medicines or nanomedicines into a targeted therapy by simply mixing the antibody and drug or by first administering the bispecific antibody followed by drug administration.
This makes it easy to develop targeted medicines without damaging their bioactivity.
Applications of Technology
- Cancer therapy
- PEGylated nanomedicines
- Nanomedicine
- PEGylated drugs
Inventor
Steve Roffler, Yu-Cheng Su
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Conditional internalization of PEGylated nanoparticles by using Anti-PEG bispecific antibodies